Immunologic Therapies in Development for EBV Driven Lymphoid Malignancies

Yongsheng Jason Chan; Seok Jin Kim; Soon Thye Lim; Choon Kiat Ong; Won Seog Kim

doi:10.1002/9781119824572.ch17

Immunologic Therapies in Development for EBV Driven Lymphoid Malignancies

Yongsheng Jason Chan, Seok Jin Kim, Soon Thye Lim, Choon Kiat Ong, Won Seog Kim

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

EBV-associated lymphomas are immune-related diseases arising from B-cell and T/NK cells. In cases where immune deficiency has been implicated in lymphomagenesis, reconstitution of immune system should be the first step. In cases that may require systemic therapy, immune checkpoint inhibitors, in particular PD1/PD-L1 inhibitors, can produce excellent clinical responses. Many EBV-targeting cell therapies are under active investigation.

Original language	English
Title of host publication	Precision Cancer Therapies
Subtitle of host publication	Volume 2: Immunologic Approaches for the Treatment of Lymphoid Malignancies: From Concept to Practice
Publisher	wiley
Pages	246-256
Number of pages	11
ISBN (Electronic)	9781119824572
ISBN (Print)	9781119824541
DOIs	https://doi.org/10.1002/9781119824572.ch17
State	Published - 1 Jan 2024
Externally published	Yes

Keywords

cellular therapy
EBV driven lymphoid malignancies
immune checkpoint inhibitors
immunologic therapy
lytic induction therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/9781119824572.ch17

Cite this

@inbook{92280612af4a4366b6a4708e0bd5c168,

title = "Immunologic Therapies in Development for EBV Driven Lymphoid Malignancies",

abstract = "EBV-associated lymphomas are immune-related diseases arising from B-cell and T/NK cells. In cases where immune deficiency has been implicated in lymphomagenesis, reconstitution of immune system should be the first step. In cases that may require systemic therapy, immune checkpoint inhibitors, in particular PD1/PD-L1 inhibitors, can produce excellent clinical responses. Many EBV-targeting cell therapies are under active investigation.",

keywords = "cellular therapy, EBV driven lymphoid malignancies, immune checkpoint inhibitors, immunologic therapy, lytic induction therapy",

author = "Chan, \{Yongsheng Jason\} and Kim, \{Seok Jin\} and Lim, \{Soon Thye\} and Ong, \{Choon Kiat\} and Kim, \{Won Seog\}",

note = "Publisher Copyright: {\textcopyright} 2024 John Wiley \& Sons Ltd.",

year = "2024",

month = jan,

day = "1",

doi = "10.1002/9781119824572.ch17",

language = "English",

isbn = "9781119824541",

pages = "246--256",

booktitle = "Precision Cancer Therapies",

publisher = "wiley",

}

Immunologic Therapies in Development for EBV Driven Lymphoid Malignancies. / Chan, Yongsheng Jason; Kim, Seok Jin; Lim, Soon Thye et al.
Precision Cancer Therapies: Volume 2: Immunologic Approaches for the Treatment of Lymphoid Malignancies: From Concept to Practice. wiley, 2024. p. 246-256.

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

TY - CHAP

T1 - Immunologic Therapies in Development for EBV Driven Lymphoid Malignancies

AU - Chan, Yongsheng Jason

AU - Kim, Seok Jin

AU - Lim, Soon Thye

AU - Ong, Choon Kiat

AU - Kim, Won Seog

PY - 2024/1/1

Y1 - 2024/1/1

N2 - EBV-associated lymphomas are immune-related diseases arising from B-cell and T/NK cells. In cases where immune deficiency has been implicated in lymphomagenesis, reconstitution of immune system should be the first step. In cases that may require systemic therapy, immune checkpoint inhibitors, in particular PD1/PD-L1 inhibitors, can produce excellent clinical responses. Many EBV-targeting cell therapies are under active investigation.

AB - EBV-associated lymphomas are immune-related diseases arising from B-cell and T/NK cells. In cases where immune deficiency has been implicated in lymphomagenesis, reconstitution of immune system should be the first step. In cases that may require systemic therapy, immune checkpoint inhibitors, in particular PD1/PD-L1 inhibitors, can produce excellent clinical responses. Many EBV-targeting cell therapies are under active investigation.

KW - cellular therapy

KW - EBV driven lymphoid malignancies

KW - immune checkpoint inhibitors

KW - immunologic therapy

KW - lytic induction therapy

UR - https://www.scopus.com/pages/publications/85193892045

U2 - 10.1002/9781119824572.ch17

DO - 10.1002/9781119824572.ch17

M3 - Chapter

AN - SCOPUS:85193892045

SN - 9781119824541

SP - 246

EP - 256

BT - Precision Cancer Therapies

PB - wiley

ER -

Immunologic Therapies in Development for EBV Driven Lymphoid Malignancies

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this